Ampio Pharmaceuticals Inc. shares fell sharply Monday, hitting a 52-week low after the company revealed that one of its lead candidates, Ampion, failed to provide better pain relief that a placebo injection in a phase III study of people suffering from osteoarthritis of the of the knee (OAK).